The Food and Drug Administration (FDA) has recently approved Foundayo, the second GLP-1 pill for treating obesity, made by Eli Lilly. This pill is taken once a day and enters the market alongside the pill form of Wegovy from Novo Nordisk, which was approved just a few months earlier.
Both companies now offer a pill option, which many patients may find easier than injections. However, the cost of these drugs and limited insurance coverage may still create barriers for potential users.
The FDA expedited Foundayo’s approval. In just 50 days, it was reviewed, marking the fastest approval for a new drug since 2002. The innovative formula, known as orforglipron, is not a peptide like previous treatments. It has been designed for easier absorption in pill form, which could provide a more convenient experience. According to Daniel Skovronsky, Eli Lilly’s chief scientific and product officer, this new chemical can mimic the effects of traditional peptides without the need for strict eating schedules.
In clinical trials, patients using Foundayo lost an average of 27.3 pounds over 72 weeks compared to just 2.2 pounds in the placebo group. Common side effects included nausea and diarrhea. However, some experts argue that the new pill may not be more effective than Wegovy, which has been challenged by Novo Nordisk. Jamey Millar, an executive from Novo Nordisk, claims there are no direct comparisons showing that orforglipron is superior for weight management.
Dr. Catherine Varney, an obesity medicine specialist, believes that the convenience of Foundayo could lead to better results for patients who may struggle with strict dosing schedules. This thought echoes a significant trend in medicine as more patients seek treatments that integrate smoothly into their lifestyles without complicating their routines.
While both drugs can be purchased at about $149 per month without insurance, Foundayo is expected to be more affordable overall. It’s also anticipated to be available in pharmacies soon, as Eli Lilly has already manufactured sufficient quantities.
For those experiencing financial barriers, cost remains a significant concern. Many patients prefer Wegovy simply because it’s priced better under certain insurance plans. Eli Lilly is expected to clarify insurance coverage shortly, with potential copays going as low as $25 a month for those enrolled with commercial insurance. For Medicare patients, it may soon be available for $50 monthly.
In conclusion, Foundayo marks an exciting development in obesity treatment. Its availability as a pill could encourage more patients to seek help, making it easier to adopt a weight-loss strategy. However, the final impact will depend on overall effectiveness and accessibility through insurance coverage.
For more information on FDA drug approvals, visit the FDA official website.
